日报更新时间：
周报更新时间：04-11 03:39
今开价：110.73
最高价：110.73
成交量：210974.0
昨收价：109.58
最低价：107.66
最新价：109.13
中文名称：Ultragenyx药业
英文名称：Ultragenyx Pharmaceutical
简介：Ultragenyx Pharmaceutical Inc.于2010年4月22日成立，是一家处于发展阶段的生物科技企业，公司随后于2011年6月在特拉华州重新注册成立
电话：1-415-4838800
Ultragenyx Pharmaceutical公司开发各种生物制剂候选产品，包括： 人类单克隆抗体KRN23，现处成人研究III期阶段，以绑定并减少成纤维细胞生长因子23的生物活性，从而提高X连锁低磷血症患者体内的异常低磷酸盐水平；以及用于不能手术的肿瘤诱导的成人骨软化症患者的治疗； 重组人β-葡萄糖醛酸酶（rhGUS），为静脉酶类替代疗法，用于治疗粘多糖贮积症7，已完成III期临床研究阶段； 重组人体保护蛋白质组织蛋白酶-A（rhPPCA） ，为酶类替代疗法，用于治疗酵素缺乏症，现处临床前开发阶段； 此外，公司还开发一系列小分子候选产品，包括酶基替代疗法triheptanoin（UX007），用于治疗脂肪酸氧化作用缺陷和脑血管屏障葡萄糖输送缺陷，现处II期临床研究阶段； 唾液酸口服制剂，用于治疗遗传性包涵体肌病变，现处扩展研究第二期阶段。Ultragenyx Pharmaceutical公司与Nobelpharma Co., Ltd.、Kyowa Hakko Kirin Co. Ltd有合作和授权协议；与Saint Louis University、AAI Pharma Services Corp.、HIBM Research Group、St. Jude Children's Research Hospital及Baylor Research Institute有授权协议。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2017-08-02 | Dallas (Jayson Donald Alexander) | Officer | Sell | 940 | 62.59 |
| 2017-07-15 | Pinion (John Richard) | Officer | Sell | 705 | 64.36 |
| 2017-06-21 | Siegall (Clay B) | Director | Buy | 1875 | -- |
| 2017-06-21 | Welch (Daniel G) | Director | Buy | 1875 | -- |
| 2017-06-21 | Dunsire (Deborah) | Director | Buy | 1875 | -- |
| 2017-06-21 | Narachi (Michael A) | Director | Buy | 1875 | -- |
| 2017-06-21 | Ekman (Lars G) | Director | Buy | 1875 | -- |
| 2017-06-21 | Fust (Matthew K.) | Director | Buy | 1875 | -- |
| 2017-06-21 | Aliski (William) | Director | Buy | 1875 | -- |
| 2017-06-19 | Parschauer (Karah Herdman) | General Counsel | Sell | 705 | 63.38 |
| 2017-05-31 | Pinion (John Richard) | Officer | Sell | 282 | 56.61 |
| 2017-05-31 | Kakkis (Emil D) | Chief Executive Officer | Sell | 1006 | 56.61 |
| 2017-05-31 | Dallas (Jayson Donald Alexander) | Officer | Sell | 320 | 56.61 |
| 2017-05-31 | Kassberg Thomas Richard | Officer | Sell | 376 | 56.61 |
| 2017-05-31 | Sharp (Shalini) | Chief Financial Officer | Sell | 376 | 56.61 |
| 2017-05-31 | Huang (Dennis Karl) | Chief Technology Officer | Sell | 282 | 56.61 |
| 2017-05-25 | Huizenga Theodore Alan | Officer | Sell | 480 | 57.46 |
| 2017-05-20 | Kakkis (Emil D) | Chief Executive Officer | Sell | 1072 | 57.47 |
| 2017-05-20 | Huizenga Theodore Alan | Officer | Sell | 166 | 57.47 |
| 2017-05-20 | Kassberg Thomas Richard | Officer | Sell | 414 | 57.47 |
| 2017-05-20 | Sharp (Shalini) | Chief Financial Officer | Sell | 414 | 57.47 |
| 2017-05-04 | Huang (Dennis Karl) | Chief Technology Officer | Sell | 705 | 61.08 |
| 2017-03-08 | Huizenga Theodore Alan | Officer | Sell | 2500 | 86.34 |
| 2017-03-01 | Sharp (Shalini) | Chief Financial Officer | Buy | 12000 | 0.82 |
| 2017-03-01 | Sharp (Shalini) | Chief Financial Officer | Sell | 12000 | 90.10 |
| 2017-02-28 | Parschauer (Karah Herdman) | General Counsel | Buy | 2000 | -- |
| 2017-02-28 | Huang (Dennis Karl) | Chief Technology Officer | Buy | 2000 | -- |
| 2017-02-28 | Dallas (Jayson Donald Alexander) | Officer | Buy | 4500 | -- |
| 2017-02-28 | Kassberg Thomas Richard | Officer | Buy | 3000 | -- |
| 2017-02-28 | Huizenga Theodore Alan | Officer | Buy | 1075 | -- |
| 第 页, 共 5 页 首页 上页 下页 末页 | |||||
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| AllianceBernstein L.P. | 1130232 | 1.97% | 122009 | 12.10% | 2019-03-31 |
| Hartford Funds Management Company, LLC | 2664599 | 4.62% | -12576 | -0.47% | 2019-07-31 |
| T. Rowe Price Associates, Inc. | 3501623 | 6.09% | 771242 | 28.25% | 2019-03-31 |
| BlackRock Inc | 4745363 | 8.26% | 268551 | 6.00% | 2019-03-31 |
| Vanguard Group Inc | 4893771 | 8.51% | 731991 | 17.59% | 2019-03-31 |
| Capital Research & Mgmt Co - Division 3 | 5568549 | 9.69% | 978695 | 21.32% | 2019-03-31 |
| Capital Research Global Investors | 6355432 | 11.06% | 499277 | 8.53% | 2019-03-31 |
| Wellington Management Company LLP | 6381870 | 11.10% | 385788 | 6.43% | 2019-03-31 |
| Capital Research and Management Company | 13648176 | 23.66% | 92210 | 0.68% | 2019-07-31 |
| FMR Inc | 2517746 | 4.38% | -429178 | -14.56% | 2019-03-31 |
| Fidelity Management and Research Company | 2507106 | 4.36% | -429178 | -14.62% | 2019-03-31 |
| BlackRock Fund Advisors | 2377393 | 4.12% | 24107 | 1.02% | 2019-07-31 |
| Fidelity Management & Research Company | 1385430 | 2.40% | -546359 | -28.28% | 2019-07-31 |
| Alkeon Capital Management, LLC | 1471733 | 2.56% | 652207 | 79.58% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 1519874 | 2.63% | 1367 | 0.09% | 2019-07-31 |
| Federated Equity Mgmt Co. Of Penn | 1703834 | 2.95% | 450000 | 35.89% | 2019-07-31 |
| Federated Investors Inc | 1749274 | 3.04% | 471955 | 36.95% | 2019-03-31 |
| Capital World Investors | 1808390 | 3.15% | 225000 | 14.21% | 2019-03-31 |
| First Trust Advisors L.P. | 1859052 | 3.23% | 387118 | 26.30% | 2019-03-31 |
| State Street Corporation | 1921711 | 3.34% | -129928 | -6.33% | 2019-03-31 |
| BlackRock Asset Management Canada Ltd | 1212178 | 2.11% | 33 | -- | 2019-05-31 |
| Geode Capital Management, LLC | 1136460 | 1.98% | 631348 | 124.99% | 2018-12-31 |
| Deutsche Asset Management Investment GmbH | 1639636 | 2.85% | 1226391 | 296.77% | 2019-05-31 |
| Fidelity SelectCo, LLC | 1093415 | 1.91% | -416029 | -27.56% | 2019-04-30 |
| ClearBridge Advisors, LLC | 1010036 | 1.97% | 164 | 0.02% | 2018-12-31 |
| SSGA Funds Management Inc | 1177465 | 2.30% | -6391 | -0.54% | 2019-02-28 |
| Ameriprise Financial Inc | 1232273 | 2.40% | -99189 | -7.45% | 2018-09-30 |
| Federated Global Inv Mgmt Corp | 1225634 | 2.42% | 900 | 0.07% | 2018-09-30 |
| BlackRock Institutional Trust Company NA | 1305178 | 2.58% | -80667 | -5.82% | 2018-06-30 |
| New Perspective Fund | 2768288 | 6.50% | 2768288 | -- | 2017-12-29 |
| State Street Corp | 1648751 | 3.29% | -368544 | -18.27% | 2018-06-30 |
| Columbia Wanger Asset Management LLC | 1230220 | 2.45% | -- | -- | 2018-07-31 |
| AllianceBernstein LP | 941868 | 1.88% | -219559 | -18.90% | 2018-06-30 |
| Pictet Asset Management SA | 640973 | 1.28% | -438396 | -40.62% | 2018-06-30 |
| Northern Trust Investments N A | 557273 | 1.11% | 38123 | 7.34% | 2018-06-30 |
| Citadel Advisors Llc | 467572 | 0.93% | -17007 | -3.51% | 2018-06-30 |
| Highline Capital Management LLC | 410000 | 0.82% | 410000 | -- | 2018-06-30 |
| Capital Guardian Trust Company | 460648 | 0.92% | -35245 | -7.11% | 2018-06-30 |
| Legg Mason Partners Fund Advisor, LLC | 386943 | 0.75% | -- | -- | 2018-08-21 |
| Adage Capital Partners Gp LLC | 489203 | 0.98% | 381703 | 355.07% | 2018-03-31 |
| NORGES BANK | 528530 | 1.20% | 6315 | 1.21% | 2017-12-31 |
| Sectoral Asset Management Inc | 378830 | 0.89% | -11382 | -2.92% | 2017-09-30 |
| Fred Alger Management Inc | 389236 | 0.88% | 22168 | 6.04% | 2017-12-31 |
| BlackRock Advisors LLC | 406573 | 0.82% | -5016 | -1.22% | 2018-02-28 |
| Brown Investment Advisory Incorporated | 341702 | 0.80% | 19205 | 5.96% | 2017-09-30 |
| Goldman Sachs Asset Management LP | 388130 | 0.91% | -1277 | -0.33% | 2017-09-30 |
| Rockefeller & Co | 400626 | 0.94% | -7753 | -1.90% | 2017-09-30 |
| Eagle Asset Management, Inc. | 475875 | 1.12% | -4904 | -1.02% | 2017-09-30 |
| Jennison Associates LLC | 498446 | 1.24% | 405 | 0.08% | 2016-09-30 |
| Wells Capital Management Inc. | 690321 | 1.72% | -638136 | -48.04% | 2016-09-30 |
| Smallcap World Fund Inc | 905807 | 2.33% | 905807 | -- | 2015-12-31 |
| Emil D. Kakkis, M.D., Ph.D. | 3345122 | 4.00% | 214823735 | 0.10% | 1999-11-30 |
| FMR LLC | 4788087 | 4.00% | 307490947 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Fidelity | 614324 | 1.06% | -- | -- | 2019-06-30 |
| Vanguard Small Cap Index | 1401438 | 2.43% | 3920 | 0.28% | 2019-06-30 |
| American Funds New Economy Fund | 1484906 | 2.57% | -- | -- | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 1507439 | 2.61% | 302 | 0.02% | 2019-06-30 |
| First Trust NYSE Arca Biotech Fund | 1516597 | 2.63% | -3654 | -0.24% | 2019-07-31 |
| American Funds SMALLCAP World Fund | 1933070 | 3.35% | -- | -- | 2019-06-30 |
| Hartford MidCap Fund | 1970343 | 3.42% | -- | -- | 2019-06-30 |
| American Funds New Perspective Fund | 3397088 | 5.89% | -- | -- | 2019-06-30 |
| American Funds Growth Fund of Amer | 4597038 | 7.97% | 61610 | 1.36% | 2019-06-30 |
| Federated Kaufmann Fund | 1257934 | 2.18% | 268600 | 27.15% | 2019-03-31 |
| iShares Russell 2000 ETF | 1199910 | 2.08% | 11361 | 0.96% | 2019-07-30 |
| Vanguard Extended Market Index Fund | 746840 | 1.29% | 17589 | 2.41% | 2019-06-30 |
| Vanguard Small Cap Growth Index Fund | 800023 | 1.39% | 8630 | 1.09% | 2019-06-30 |
| American Funds IS | 822800 | 1.43% | -- | -- | 2019-06-30 |
| American Funds Fundamental Invs | 917800 | 1.59% | 35800 | 4.06% | 2019-06-30 |
| Vanguard Explorer Fund | 935100 | 1.62% | 195100 | 26.36% | 2019-03-31 |
| SPDR | 984037 | 1.71% | 15300 | 1.58% | 2019-07-31 |
| T. Rowe Price Health Sciences Fund | 1028852 | 1.78% | 154768 | 17.71% | 2019-06-30 |
| T. Rowe Price New Horizons Fund | 1177882 | 2.04% | 316223 | 36.70% | 2019-06-30 |
| iShares US Small Cap ETF (CAD-Hedged) | 1065842 | 1.85% | -1791 | -0.17% | 2019-05-30 |
| DWS Verm | 817664 | 1.42% | 613248 | 300.00% | 2019-04-30 |
| Vanguard Small Cap Index Fund | 1398418 | 2.43% | 8961 | 0.64% | 2019-04-30 |
| iShares Nasdaq Biotechnology ETF | 587919 | 1.15% | -2863 | -0.48% | 2019-03-29 |
| VA CollegeAmerica The Gr Fd of Amer | 4322964 | 8.43% | -- | -- | 2018-12-31 |
| VA CollegeAmerica New Perspective Fd | 2768288 | 5.40% | -- | -- | 2018-12-31 |
| VA CollegeAmerica SMALLCAP Wld Fd | 1831670 | 3.57% | -133200 | -6.78% | 2018-12-31 |
| HBM Healthcare Investments AG | 500000 | 0.98% | 254499 | 103.67% | 2018-12-31 |
| VA CollegeAmerica The New Economy Fd | 1331106 | 2.60% | 179000 | 15.54% | 2018-12-31 |
| VA CollegeAmerica Fundamental Inv | 495000 | 0.98% | 495000 | -- | 2018-12-31 |
| Columbia Acorn International Fund | 462028 | 0.91% | -82390 | -15.13% | 2018-11-30 |
| First Trust NYSE Arca Biotech ETF | 895791 | 1.78% | -- | -- | 2018-09-13 |
| Columbia Acorn International Z | 590087 | 1.18% | -- | -- | 2018-07-31 |
| iShares Nasdaq Biotechnology | 564844 | 1.11% | -1074 | -0.19% | 2018-09-12 |
| VA CollegeAmerica Grth Fund of Amer 529F | 3198964 | 6.38% | 233269 | 7.87% | 2018-06-30 |
| VA CollegeAmerica New Perspective 529E | 2768288 | 5.52% | -- | -- | 2018-06-30 |
| VA CollegeAmerica Smcap World 529E | 1775970 | 3.54% | -- | -- | 2018-06-30 |
| Hartford MidCap A | 1604618 | 3.20% | -224985 | -12.30% | 2018-07-31 |
| VA CollegeAmerica New Economy 529F | 1408408 | 2.81% | -- | -- | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 1181287 | 2.35% | 1104 | 0.09% | 2018-07-31 |
| T. Rowe Price Health Sciences | 1012757 | 2.02% | 194041 | 23.70% | 2018-06-30 |
| Federated Kaufmann R | 989334 | 1.97% | -- | -- | 2018-06-30 |
| T. Rowe Price New Horizons | 880841 | 1.76% | 189208 | 27.36% | 2018-06-30 |
| Vanguard Small Cap Growth Index Inv | 679544 | 1.35% | 10226 | 1.53% | 2018-07-31 |
| American Funds NVIT Growth-Income II | 695200 | 1.39% | -- | -- | 2018-06-30 |
| Vanguard Explorer Inv | 686920 | 1.37% | 196920 | 40.19% | 2018-06-30 |
| Vanguard Extended Market Idx Inv | 611281 | 1.22% | 3800 | 0.63% | 2018-07-31 |
| iShares Russell 2000 Growth | 466077 | 0.90% | -438 | -0.09% | 2018-08-09 |
| Columbia Acorn Z | 509364 | 1.07% | -28287 | -5.26% | 2018-01-31 |
| Fidelity Advisor | 404027 | 0.95% | -- | -- | 2017-12-31 |
| BlackRock Health Sciences Opps Inv A | 389500 | 0.91% | -- | -- | 2017-11-30 |
| Prudential Jennison Health Sciences A | 423027 | 1.04% | -- | -- | 2016-12-31 |
| Wells Fargo Growth A | 451320 | 1.10% | -16090 | -3.44% | 2016-12-31 |
| VA CollegeAmerica New Economy | 1531849 | 4.00% | -729800 | -32.30% | 2015-09-30 |
| VA CollegeAmerica Small Cap World | 1175906 | 3.00% | -194307 | -14.20% | 2015-09-30 |
| Columbia Acorn Fund | 881105 | 2.30% | -- | -- | 2015-09-30 |
| Fidelity® Select Health Care Portfolio | 760000 | 2.00% | -40000 | -5.00% | 2015-09-30 |
| Fidelity® Growth Company Fund | 751300 | 1.90% | -2223 | -0.30% | 2015-09-30 |
| American Funds IS® Gbl Sm Cap | 736206 | 1.90% | -100000 | -12.00% | 2015-09-30 |
| Wells Fargo Advantage Growth Fund | 729000 | 1.90% | 160000 | 28.10% | 2015-09-30 |
| iShares Russell 2000 (AU) | 608616 | 1.50% | -768 | -0.10% | 2015-11-19 |
| Fidelity Advisor® Biotechnology Fund | 366427 | 0.90% | -- | -- | 2015-09-30 |
| Fidelity® Select Biotechnology Portfolio | 1976978 | 5.10% | -- | -- | 2015-09-30 |
| Thomas Richard Kassberg | Founder of Plexxikon, Inc., Thomas Richard Kassberg is Chief Business Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc. Mr. Kassberg previously held the position of Vice President-Business Development of Corium International, Inc., Senior Director-Corporate Licensing at Pharmacia, Inc., Principal at Bristol-Myers Squibb Co., SVP-Corporate Development & Commercial Operations at InterMune, Inc., Senior Vice President-Business Development for Sugen LLC, Vice President-Business & Corporate Development at Plexxikon, Inc., Chief Business Officer at Melinta Subsidiary Corp. and Executive Vice President-Corporate Development at Proteolix, Inc. Thomas Richard Kassberg received an MBA from Northwestern University and an undergraduate degree from Gustavus Adolphus College. |
|---|---|
| Deborah L. Dunsire | Presently, Deborah L. Dunsire occupies the position of President & Chief Executive Officer at H. Lundbeck A. She is also Secretary at Biotechnology Innovation Organization and on the board of 7 other companies. Dr. Dunsire previously occupied the position of President, Chief Executive Officer & Director at XTuit Pharmaceuticals, Inc., President, Chief Executive Officer & Director at FORUM Pharmaceuticals, Inc., Director at Takeda Pharmaceutical Co., Ltd. and President, Chief Executive Officer & Director at Takeda Oncology Co. (a subsidiary of Takeda Pharmaceutical Co., Ltd.) and Vice President-Oncology Business Unit at Novartis AG and Senior Vice President-North America Oncology at Novartis Oncology, Inc. (a subsidiary of Novartis AG). Dr. Dunsire received a doctorate from the University of the Witwatersrand. |
| Theodore A. Huizenga | Theodore A. Huizenga holds the position of Vice President & Controller at Ultragenyx Pharmaceutical, Inc. Mr. Huizenga received an undergraduate degree from Calvin College. |
| Emil D. Kakkis | Emil D. Kakkis founded Ultragenyx Pharmaceutical, Inc. and Everylife Foundation for Rare Diseases. Dr. Kakkis occupies the position of President, Chief Executive Officer & Director at Ultragenyx Pharmaceutical, Inc. He is also on the board of Emil Kakkis & Jenny Soriano Living Trust and President of Everylife Foundation for Rare Diseases. In his past career he was Chief Medical Officer & Senior Vice President for BioMarin Pharmaceutical, Inc. and Assistant Professor at Harbor-UCLA Medical Center. Emil D. Kakkis received an undergraduate degree from Pomona College and a doctorate from David Geffen School of Medicine. |
| Clay B. Siegall | Clay B. Siegall founded Seattle Genetics, Inc. Presently, he is Chairman, President & Chief Executive Officer at this company. Dr. Siegall is also on the board of 6 other companies. In his past career he was Principal Scientist at Bristol-Myers Squibb Pharmaceutical Research Institute. He received an undergraduate degree from the University of Maryland and a doctorate from George Washington University. |
| Daniel G. Welch | Mr. Daniel G. Welch is Executive Partner at Sofinnova Ventures, Inc., Independent Director at Hyperion Therapeutics, Inc., and Independent Director at Seattle Genetics, Inc. He has over 30 years of experience across both multi-national pharmaceutical companies and biotech companies. Mr. Welch joined Sofinnova Ventures in 2015. Most recently, he was the Chairman, CEO and President of InterMune. Beginning in 2003, he led a comprehensive company turn-around, refocusing the company's development efforts. He built the InterMune development and commercial teams that delivered the successful approval of Esbriet. In October 2014, Roche acquired InterMune. From August 2002 to January 2003, he served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., a pharmaceutical company. From October 2000 to June 2002, he served as president of the pharmaceutical division of Elan Corporation, PLC (acquired by Perrigo). From September 1987 to August 2000, he served in various senior management roles at Sanofi-Synthelabo (now Sanofi) and its predecessor companies Sanofi and Sterling Winthrop. During his time at Sanofi, he led the successful worldwide launches of Plavix, Eloxatin and Avapro as Vice President of Worldwide Marketing and he served as COO of the U.S. business. From November 1980 to September 1987, he was with American Critical Care, a division of American Hospital Supply. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina. |
| Matthew K. Fust | Mr. Matthew K. Fust is an Independent Director at Crinetics Pharmaceuticals, Inc., an Independent Director at Dermira, Inc., an Independent Director at MacroGenics, Inc., an Independent Director at Atara Biotherapeutics, Inc. and an Independent Director at Ultragenyx Pharmaceutical, Inc. He is on the Board of Directors at Crinetics Pharmaceuticals, Inc., Blackthorn Therapeutics, Inc., Dermira, Inc., MacroGenics, Inc., Atara Biotherapeutics, Inc. and Ultragenyx Pharmaceutical, Inc. Mr. Fust was previously employed as a Chief Financial Officer & Executive Vice President by Onyx Pharmaceuticals, Inc., an Independent Director by Sunesis Pharmaceuticals, Inc., a Chief Financial Officer & Executive Vice President by Jazz Pharmaceuticals, Inc., a Chief Financial Officer by Perlegen Sciences, Inc., a Chief Financial Officer & Senior Vice President by ALZA Corp., and a Manager-Healthcare Strategy Practice by Anderson Consulting Team. He received his undergraduate degree from the University of Minnesota and an MBA from Stanford Graduate School of Business. |
| Camille L. Bedrosian | Presently, Camille L. Bedrosian occupies the position of Chief Medical Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc. Dr. Bedrosian is also Member of American Society of Hematology, Member of American Society of Nephrology and Member of American Society of Clinical Oncology. Camille L. Bedrosian previously was Chief Medical Officer & Senior Vice President for Alexion Pharmaceuticals, Inc., Member of American Association for Cancer Research, Chief Medical Officer & Vice President at ARIAD Pharmaceuticals, Inc., Senior Director-Oncology & Hematology at Genetics Institute LLC, Member of American Association for the Advancement of Science, Assistant Professor at Duke University Medical Center and Member of Duke Comprehensive Cancer Center. She received an undergraduate degree from Harvard University, a graduate degree from Massachusetts Institute of Technology and a doctorate from Harvard Medical School. |
| John Richard Pinion | John Richard Pinion is on the board of Aroa Biosurgery Ltd. and Chief Quality Operations Officer at Ultragenyx Pharmaceutical, Inc. In his past career he was Vice President-Quality at Baxter BioScience Corp. and Senior Vice President-Quality & Compliance at Genentech, Inc. He received an undergraduate degree from West Virginia University. |
| Lars G. Ekman | Lars G. Ekman, M.D., Ph.D., is Chairman of our Board of Directors, a position he has held since 2012. He is an executive partner at Sofinnova Ventures, Inc. (a venture capital firm), a position he has held since 2008. Dr. Ekman is also Chairman of the Board of Sophiris Bio Inc. (a biopharmaceutical company), where he also served as President from 2011 to 2012. He also is Chairman of the Board of Amarin Corporation plc, serves as a director of Spark Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc., served as a director of Ocera Therapeutics, Inc. (from 2009 to 2015) and served as a director of InterMune Inc. (from 2006 to 2014). Dr. Ekman co-founded Cebix Incorporated, where he served as Chief Executive Officer from 2009 to 2012. He was President of Research & Development at Elan Corporation, plc (from 2001 to 2007), where he also served as a director (from 2005 to 2012). From 1997 to 2001, Dr. Ekman was Executive Vice President, Research & Development at Schwarz Pharma AG. Prior to that, he held various senior positions at Pharmacia Corporation. Dr. Ekman is a board-certified surgeon with a Ph.D. in experimental biology, and has held several clinical and academic positions in both the United States and Europe. He earned his Ph.D. and M.D. from the University of Gothenburg, Sweden. Dr. Ekman has served on our Board since 2012. Age: 67 |
| Shalini Sharp | Shalini Sharp is Chief Financial Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc. and Treasurer & Vice President for Dimension Therapeutics, Inc. (a subsidiary of Ultragenyx Pharmaceutical, Inc.). She is also on the board of Array BioPharma, Inc., Global Alliance for TB Drug Development, Precision BioSciences, Inc. and Sutro Biopharma, Inc. She previously was Independent Director at Agenus, Inc., Chairman & Chief of Staff at Elan Pharmaceuticals LLC and Director-Strategic Planning at Elan Corp. Plc. Shalini Sharp received an undergraduate degree and an MBA from Harvard University. |
| Michael A. Narachi | Michael A. Narachi is a businessperson who has been at the head of 6 different companies and presently occupies the position of President, Chief Executive Officer & Director at CODA Biotherapeutics, Inc. He is also on the board of Biotechnology Innovation Organization and Ultragenyx Pharmaceutical, Inc. In the past Mr. Narachi held the position of Chairman at Naryx Pharma, Inc., Chairman, President & Chief Executive Officer for Ren Pharmaceuticals, Inc., Director at AMAG Pharmaceuticals, Inc., Vice President for Amgen, Inc., Director-Clinical Operations at Thousand Oaks Corp., Chairman at Celladon Corp., President, Chief Executive Officer & Director at Orexigen Therapeutics, Inc. and Vice President-Development at Amgen KK. Mr. Narachi received an undergraduate degree and a graduate degree from the University of California, Davis and an MBA from UCLA Anderson School of Management. |
| Dennis Karl Huang | Dennis Karl Huang occupies the position of Chief Technical Operations Officer & Senior VP at Ultragenyx Pharmaceutical, Inc. He is also on the board of Bonti, Inc. He previously occupied the position of Senior VP-Manufacturing & Supply Chain at InterMune, Inc. and VP-Biologics Manufacturing & Development at Allergan, Inc. Mr. Huang received an undergraduate degree from Knox College. |
| William E. Aliski | William E. Aliski is on the board of Ultragenyx Pharmaceutical, Inc. and Applied Genetic Technologies Corp. Mr. Aliski previously occupied the position of General Manager-BioMarin Europe at BioMarin Pharmaceutical, Inc. and Vice President & General Manager at BioMarin Europe Ltd. (a subsidiary of BioMarin Pharmaceutical, Inc.), Vice President-Patient & Product Services at Genzyme Corp., Chief Commercial Officer & Senior Vice President at FoldRx Pharmaceuticals, Inc. and Vice President-Commercial Operations at Transkaryotic Therapies, Inc. He received an undergraduate degree and a graduate degree from Boston College and a graduate degree from Harvard Kennedy School of Government. |
| Erik C. Harris | Erik C. Harris is Chief Commercial Officer & Executive VP for Ultragenyx Pharmaceutical, Inc. In the past Mr. Harris held the position of Manager-Sales & Marketing at Bristol-Myers Squibb Co., Head-Sales & Marketing at Genentech, Inc., Senior Director-Marketing & Sales at Elan Corp. Plc, Vice President-Marketing of InterMune, Inc. and Vice President-Marketing & Sales at Crescendo Bioscience, Inc. Mr. Harris received an undergraduate degree from United States Naval Academy and an MBA from The Wharton School of the University of Pennsylvania. |
| Thomas Richard Kassberg | Founder of Plexxikon, Inc., Thomas Richard Kassberg is Chief Business Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc. Mr. Kassberg previously held the position of Vice President-Business Development of Corium International, Inc., Senior Director-Corporate Licensing at Pharmacia, Inc., Principal at Bristol-Myers Squibb Co., SVP-Corporate Development & Commercial Operations at InterMune, Inc., Senior Vice President-Business Development for Sugen LLC, Vice President-Business & Corporate Development at Plexxikon, Inc., Chief Business Officer at Melinta Subsidiary Corp. and Executive Vice President-Corporate Development at Proteolix, Inc. Thomas Richard Kassberg received an MBA from Northwestern University and an undergraduate degree from Gustavus Adolphus College. |
| Vimal Srivastava | Vimal Srivastava is Senior VP-Development & Alliance Management at Ultragenyx Pharmaceutical, Inc. In his past career he occupied the position of Director-Program Management at BioMarin Pharmaceutical, Inc., Global Manager-Program at Amgen, Inc. and Senior Director-Portfolio & Project Management at Janssen Alzheimer Immunotherapy. Mr. Srivastava received an undergraduate degree from Banaras Hindu University, a graduate degree from St. John's University and a graduate degree from The Johns Hopkins University. |
| Danielle Keatley | Currently, Danielle Keatley is Head-IR & Corporate Communications at Ultragenyx Pharmaceutical, Inc. and Media Relations Contact at Onyx Pharmaceuticals, Inc. |
| Javier San Martin | Javier San Martin is Senior VP-Global Clinical Development at Ultragenyx Pharmaceutical, Inc. He previously was Principal at Eli Lilly & Co., Senior Vice President-Clinical Development at Alder Biopharmaceuticals, Inc. and Executive Director-Bone Therapeutic Area at Amgen, Inc. He received a doctorate from Universidad de Buenos Aires. |
| Jayson Donald Alexander Dallas | Mr. Jayson D. Dallas is a Chief Commercial Officer & Senior Vice President at Ultragenyx Pharmaceutical, Inc. He is on the Board of Directors at Arena Pharmaceuticals, Inc. Mr. Dallas was previously employed as a General Manager by Roche Diagnostics Ltd. and a VP-Global Product Strategy Inflammation by Genentech, Inc. He received his undergraduate degree from Knox College, an MBA from Ashridge Business School and a doctorate degree from the University of the Witwatersrand. |
| Alison Skrinar | Alison Skrinar is Senior Director-Clinical Sciences at Ultragenyx Pharmaceutical, Inc. She received an undergraduate degree from Emory University and a doctorate and a graduate degree from The University of Alabama. |
| Christine Murray | Christine Murray holds the position of Senior Vice President-Global Regulatory Affairs at Ultragenyx Pharmaceutical, Inc. She is also on the board of Eiger BioPharmaceuticals, Inc. In her past career Ms. Murray was Vice President-Regulatory Affairs at Achaogen, Inc. and Vice President-Global Regulatory Affairs at Horizon Pharmaceutical LLC. Ms. Murray received an undergraduate degree from The University of Liverpool and a graduate degree from Newcastle University. |
| Matthew K. Fust | Dr. Michael Vellard is Vice President-Research at Ultragenyx Pharmaceutical, Inc. He received his undergraduate degree from Universit�0�1�0�8 Claude Bernard Lyon 1, a graduate degree from Universit�0�1�0�8 Claude Bernard Lyon 1, a doctorate degree from Universit�0�1�0�8 Pierre et Marie Curie, a doctorate degree from Universit�0�1�0�8 Paris Diderot-Paris 7, and a doctorate degree from Universit�0�1�0�8 Paris-Sud 11. |
| Samuel C. Wadsworth | Samuel C. Wadsworth is Chief Scientific Officer-Ultragenyx Gene Therapy at Ultragenyx Pharmaceutical, Inc. He previously held the position of Principal at Sanofi-Aventis U.S. LLC and Vice President-Translational Research at Genzyme Corp. He received an undergraduate degree from The University of Chicago and an undergraduate degree from Southern Illinois University. |
| Dennis Karl Huang | Dennis Karl Huang occupies the position of Chief Technical Operations Officer & Senior VP at Ultragenyx Pharmaceutical, Inc. He is also on the board of Bonti, Inc. He previously occupied the position of Senior VP-Manufacturing & Supply Chain at InterMune, Inc. and VP-Biologics Manufacturing & Development at Allergan, Inc. Mr. Huang received an undergraduate degree from Knox College. |
| Eric Crombez | Eric Crombez is Chief Medical Officer-Gene Therapy Development at Ultragenyx Pharmaceutical, Inc. He previously held the position of Medical Director of Shire LLC, Chief Medical Officer-Ultragenyx Gene Therapy at Dimension Therapeutics, Inc. and Assistant Professor at the University of California, Los Angeles. He received an undergraduate degree from the University of Michigan and a doctorate from The Wayne State University School of Medicine. |
| Karah Parschauer | Ms. Karah Parschauer is a Secretary, Director & Vice President at Dimension Therapeutics, Inc., an Executive Vice President & General Counsel at Ultragenyx Pharmaceutical, Inc., a Member at Illinois State Bar Association and a Member at The State Bar of California. She is on the Board of Directors at Evolus, Inc., Arcturus Therapeutics Holdings, Inc., Dimension Therapeutics, Inc., Arcturus Therapeutics, Inc. and Easter Seals Southern California, Inc. Ms. Parschauer was previously employed as a Vice President & Associate General Counsel by Allergan Plc and an Associate Attorney by Latham & Watkins LLP. She received her undergraduate degree from Miami University and a graduate degree from Harvard Law School. |
| Shehnaaz Suliman | Shehnaaz Suliman is on the board of Ultragenyx Pharmaceutical, Inc. and Parvus Therapeutics, Inc. In the past she held the position of Senior VP-Corporate Development & Strategy at Theravance Biopharma, Inc. and Vice President-Global Therapeutic at Roche Holding AG. Shehnaaz Suliman received an MBA from Sa�0�1�0�4d Business School, a graduate degree from the University of Oxford and an undergraduate degree and a doctorate from the University of Cape Town. |
| Wladimir Hogenhuis | Currently, Wladimir Hogenhuis holds the position of Chief Operating Officer of Ultragenyx Pharmaceutical, Inc. In his past career Mr. Hogenhuis held the position of General Manager-Neuroscience at Merck & Co., Inc. He received a doctorate from the University of Leiden and an MBA from The Wharton School of the University of Pennsylvania. |
| Javier San Martin | Javier San Martin is Senior Vice President-Global Clinical Development at Ultragenyx Pharmaceutical, Inc. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论